The in vitro cancer diagnostics market size has grown strongly in recent years. It will grow from $11.49 billion in 2025 to $12.36 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising cancer prevalence, adoption of molecular diagnostics, development of immunoassay kits, expansion of diagnostic laboratories, advancements in reagent technologies.
The in vitro cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $16.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to AI-enabled predictive analytics, expansion in personalized oncology, development of high-throughput sequencing platforms, growth in point-of-care diagnostics, adoption of cloud-based diagnostic software. Major trends in the forecast period include biomarker-based detection, genetic profiling tools, multiplex assay development, integration with laboratory information systems (lims), rapid diagnostic kits.
The rising adoption of liquid biopsy technologies is expected to enhance the growth of the in vitro cancer diagnostics market in the coming years. Liquid biopsy technologies refer to minimally invasive diagnostic methods that detect and analyze biomarkers such as circulating tumor DNA, circulating tumor cells, or exosomes present in body fluids like blood, urine, or saliva to monitor disease presence, progression, or response to treatment, particularly in cancer. The use of liquid biopsy technologies is increasing due to advancements in isolating and analyzing circulating tumor DNA and circulating tumor cells from blood and other body fluids. In vitro cancer diagnostic solutions are experiencing higher demand as the rapid adoption of liquid biopsy technologies encourages companies to implement non invasive and real time molecular profiling tools for cancer detection and treatment guidance. For example, in May 2025, according to NHS England, a UK based public healthcare system, the new liquid biopsy blood test rollout in the UK is expected to benefit up to 15,000 patients with suspected lung cancer and 5,000 women with advanced breast cancer annually, expanding from about 2,200 patients tested during the early 2025 rollout to an estimated 20,000 patients per year by 2028. Therefore, the rising adoption of liquid biopsy technologies is enhancing the growth of the in vitro cancer diagnostics market.
Leading companies operating in the in vitro cancer diagnostics market are emphasizing the development of AI-driven cancer diagnostics to improve patient outcomes and advance personalized healthcare. AI-driven cancer diagnostics involve the use of artificial intelligence to analyze medical and molecular data from patient samples, imaging, or genetic tests, enabling highly accurate detection, diagnosis, and prediction of cancer. For instance, in September 2024, Roche, a Switzerland-based pharmaceutical company, introduced the Digital Pathology Open Environment, a collaborative platform that securely integrates advanced AI-based image analysis tools from Roche and multiple third-party developers. The platform allows pathologists to access innovative algorithms within Roche’s Navify Digital Pathology enterprise software, enhancing diagnostic precision and workflow efficiency. By fostering collaboration and data sharing, the platform accelerates innovation in cancer diagnostics and research, supports precision medicine, and enables more effective targeted treatments, expanding global access to advanced digital pathology solutions.
In February 2024, Veracyte Inc., a US-based molecular diagnostics company, acquired C2i Genomics, Inc. for an undisclosed amount. Through this acquisition, Veracyte aims to expand its presence across the cancer care continuum by incorporating AI-driven whole-genome minimal residual disease testing to enhance treatment monitoring and detect disease recurrence. C2i Genomics Inc. is a US-based biotechnology company that provides in vitro cancer diagnostics.
Major companies operating in the in vitro cancer diagnostics market are F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Illumina Inc, Hologic Inc, Qiagen N.V, Bio-Rad Laboratories Inc, Agilent Technologies, Becton, Dickinson and Company (BD), Sysmex Corporation, LabCorp Holding Corp., Guardant Health, Quest Diagnostics, Exact Sciences, Myriad Genetics Inc, Natera Inc., NeoGenomics Laboratories, NanoString Technologies Inc, Caris Life Sciences, Transasia Bio-Medicals Ltd, Autobio Diagnostics Co Ltd, QuidelOrtho Corporation, Cancer Diagnostics Inc, Predicine Inc, Strata Oncology, Biocept Inc, Lucence Diagnostics.
North America was the largest region in the in vitro cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in vitro cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the in vitro cancer diagnostics market by increasing costs of instruments, kits, reagents, and software components. Kits and instruments are most affected, particularly in North America and Europe due to import dependence. Positive effects include stimulation of local manufacturing, innovation in cost-efficient diagnostic kits, and improved domestic production capabilities.
The in vitro cancer diagnostics market research report is one of a series of new reports that provides in vitro cancer diagnostics market statistics, including in vitro cancer diagnostics industry global market size, regional shares, competitors with a in vitro cancer diagnostics market share, detailed in vitro cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro cancer diagnostics industry. This in vitro cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
In vitro cancer diagnostics refers to laboratory-based tests conducted on samples such as blood, tissue, or other body fluids to detect, monitor, or evaluate cancer outside the human body. These diagnostics employ techniques like molecular assays, biomarker analysis, and genetic profiling to identify the presence or progression of cancer. They support early detection, accurate diagnosis, and informed treatment planning for patients.
The key product types in in vitro cancer diagnostics include kits, instruments, reagents, software, and consumables. Kits are ready-to-use sets of reagents and materials designed for diagnostic testing, enabling biomarker detection, supporting disease monitoring, and assisting in treatment evaluation. Technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry, and others. These diagnostics are applied across multiple cancer types, including breast cancer, lung cancer, colorectal cancer, and prostate cancer, and serve end users such as hospitals, diagnostic laboratories, research institutes, home care settings, and others.
The in vitro cancer diagnostics market consists of revenues earned by entities by providing services such as molecular diagnostic testing, biopsy and cytology analysis, companion diagnostic services, and next-generation sequencing (NGS) services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro cancer diagnostics market also includes sales of cancer biomarker kits, molecular diagnostic assays, flow cytometry kits, tissue-based diagnostic kits, and genomic testing panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The in vitro cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $16.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to AI-enabled predictive analytics, expansion in personalized oncology, development of high-throughput sequencing platforms, growth in point-of-care diagnostics, adoption of cloud-based diagnostic software. Major trends in the forecast period include biomarker-based detection, genetic profiling tools, multiplex assay development, integration with laboratory information systems (lims), rapid diagnostic kits.
The rising adoption of liquid biopsy technologies is expected to enhance the growth of the in vitro cancer diagnostics market in the coming years. Liquid biopsy technologies refer to minimally invasive diagnostic methods that detect and analyze biomarkers such as circulating tumor DNA, circulating tumor cells, or exosomes present in body fluids like blood, urine, or saliva to monitor disease presence, progression, or response to treatment, particularly in cancer. The use of liquid biopsy technologies is increasing due to advancements in isolating and analyzing circulating tumor DNA and circulating tumor cells from blood and other body fluids. In vitro cancer diagnostic solutions are experiencing higher demand as the rapid adoption of liquid biopsy technologies encourages companies to implement non invasive and real time molecular profiling tools for cancer detection and treatment guidance. For example, in May 2025, according to NHS England, a UK based public healthcare system, the new liquid biopsy blood test rollout in the UK is expected to benefit up to 15,000 patients with suspected lung cancer and 5,000 women with advanced breast cancer annually, expanding from about 2,200 patients tested during the early 2025 rollout to an estimated 20,000 patients per year by 2028. Therefore, the rising adoption of liquid biopsy technologies is enhancing the growth of the in vitro cancer diagnostics market.
Leading companies operating in the in vitro cancer diagnostics market are emphasizing the development of AI-driven cancer diagnostics to improve patient outcomes and advance personalized healthcare. AI-driven cancer diagnostics involve the use of artificial intelligence to analyze medical and molecular data from patient samples, imaging, or genetic tests, enabling highly accurate detection, diagnosis, and prediction of cancer. For instance, in September 2024, Roche, a Switzerland-based pharmaceutical company, introduced the Digital Pathology Open Environment, a collaborative platform that securely integrates advanced AI-based image analysis tools from Roche and multiple third-party developers. The platform allows pathologists to access innovative algorithms within Roche’s Navify Digital Pathology enterprise software, enhancing diagnostic precision and workflow efficiency. By fostering collaboration and data sharing, the platform accelerates innovation in cancer diagnostics and research, supports precision medicine, and enables more effective targeted treatments, expanding global access to advanced digital pathology solutions.
In February 2024, Veracyte Inc., a US-based molecular diagnostics company, acquired C2i Genomics, Inc. for an undisclosed amount. Through this acquisition, Veracyte aims to expand its presence across the cancer care continuum by incorporating AI-driven whole-genome minimal residual disease testing to enhance treatment monitoring and detect disease recurrence. C2i Genomics Inc. is a US-based biotechnology company that provides in vitro cancer diagnostics.
Major companies operating in the in vitro cancer diagnostics market are F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers AG, Illumina Inc, Hologic Inc, Qiagen N.V, Bio-Rad Laboratories Inc, Agilent Technologies, Becton, Dickinson and Company (BD), Sysmex Corporation, LabCorp Holding Corp., Guardant Health, Quest Diagnostics, Exact Sciences, Myriad Genetics Inc, Natera Inc., NeoGenomics Laboratories, NanoString Technologies Inc, Caris Life Sciences, Transasia Bio-Medicals Ltd, Autobio Diagnostics Co Ltd, QuidelOrtho Corporation, Cancer Diagnostics Inc, Predicine Inc, Strata Oncology, Biocept Inc, Lucence Diagnostics.
North America was the largest region in the in vitro cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in vitro cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the in vitro cancer diagnostics market by increasing costs of instruments, kits, reagents, and software components. Kits and instruments are most affected, particularly in North America and Europe due to import dependence. Positive effects include stimulation of local manufacturing, innovation in cost-efficient diagnostic kits, and improved domestic production capabilities.
The in vitro cancer diagnostics market research report is one of a series of new reports that provides in vitro cancer diagnostics market statistics, including in vitro cancer diagnostics industry global market size, regional shares, competitors with a in vitro cancer diagnostics market share, detailed in vitro cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro cancer diagnostics industry. This in vitro cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
In vitro cancer diagnostics refers to laboratory-based tests conducted on samples such as blood, tissue, or other body fluids to detect, monitor, or evaluate cancer outside the human body. These diagnostics employ techniques like molecular assays, biomarker analysis, and genetic profiling to identify the presence or progression of cancer. They support early detection, accurate diagnosis, and informed treatment planning for patients.
The key product types in in vitro cancer diagnostics include kits, instruments, reagents, software, and consumables. Kits are ready-to-use sets of reagents and materials designed for diagnostic testing, enabling biomarker detection, supporting disease monitoring, and assisting in treatment evaluation. Technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry, and others. These diagnostics are applied across multiple cancer types, including breast cancer, lung cancer, colorectal cancer, and prostate cancer, and serve end users such as hospitals, diagnostic laboratories, research institutes, home care settings, and others.
The in vitro cancer diagnostics market consists of revenues earned by entities by providing services such as molecular diagnostic testing, biopsy and cytology analysis, companion diagnostic services, and next-generation sequencing (NGS) services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro cancer diagnostics market also includes sales of cancer biomarker kits, molecular diagnostic assays, flow cytometry kits, tissue-based diagnostic kits, and genomic testing panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. in Vitro Cancer Diagnostics Market Characteristics
3. in Vitro Cancer Diagnostics Market Supply Chain Analysis
4. Global in Vitro Cancer Diagnostics Market Trends and Strategies
5. in Vitro Cancer Diagnostics Market Analysis of End Use Industries
7. Global in Vitro Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global in Vitro Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. in Vitro Cancer Diagnostics Market Segmentation
10. in Vitro Cancer Diagnostics Market Regional and Country Analysis
11. Asia-Pacific in Vitro Cancer Diagnostics Market
12. China in Vitro Cancer Diagnostics Market
13. India in Vitro Cancer Diagnostics Market
14. Japan in Vitro Cancer Diagnostics Market
15. Australia in Vitro Cancer Diagnostics Market
16. Indonesia in Vitro Cancer Diagnostics Market
17. South Korea in Vitro Cancer Diagnostics Market
18. Taiwan in Vitro Cancer Diagnostics Market
19. South East Asia in Vitro Cancer Diagnostics Market
20. Western Europe in Vitro Cancer Diagnostics Market
21. UK in Vitro Cancer Diagnostics Market
22. Germany in Vitro Cancer Diagnostics Market
23. France in Vitro Cancer Diagnostics Market
24. Italy in Vitro Cancer Diagnostics Market
25. Spain in Vitro Cancer Diagnostics Market
26. Eastern Europe in Vitro Cancer Diagnostics Market
27. Russia in Vitro Cancer Diagnostics Market
28. North America in Vitro Cancer Diagnostics Market
29. USA in Vitro Cancer Diagnostics Market
30. Canada in Vitro Cancer Diagnostics Market
31. South America in Vitro Cancer Diagnostics Market
32. Brazil in Vitro Cancer Diagnostics Market
33. Middle East in Vitro Cancer Diagnostics Market
34. Africa in Vitro Cancer Diagnostics Market
36. in Vitro Cancer Diagnostics Market Competitive Landscape and Company Profiles
37. in Vitro Cancer Diagnostics Market Other Major and Innovative Companies
40. in Vitro Cancer Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
In Vitro Cancer Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses in vitro cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for in vitro cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in vitro cancer diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Kits; Instruments; Reagents; Software; Consumables2) By Technology: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Fluorescence In Situ Hybridization (FISH); Immunohistochemistry; Other Technologies
3) By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Applications
4) By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End Users
Subsegments:
1) By Kits: Immunoassay Kits; Polymerase Chain Reaction (PCR) Kits; Enzyme-Linked Immunosorbent Assay (ELISA) Kits; Flow Cytometry Kits2) By Instruments: Polymerase Chain Reaction (PCR) Instruments; Sequencers; Flow Cytometers; Imaging Systems
3) By Reagents: Enzymes; Buffers; Probes; Stains
4) By Software: Data Analysis Software; Imaging Software; Laboratory Information Management System (LIMS) Software; Diagnostic Reporting Software
5) By Consumables: Microplates; Pipette Tips; Tubes; Slides
Companies Mentioned: F. Hoffmann-La Roche Ltd; Danaher Corporation; Abbott Laboratories; Thermo Fisher Scientific; Siemens Healthineers AG; Illumina Inc; Hologic Inc; Qiagen N.V; Bio-Rad Laboratories Inc; Agilent Technologies; Becton; Dickinson and Company (BD); Sysmex Corporation; LabCorp Holding Corp.; Guardant Health; Quest Diagnostics; Exact Sciences; Myriad Genetics Inc; Natera Inc.; NeoGenomics Laboratories; NanoString Technologies Inc; Caris Life Sciences; Transasia Bio-Medicals Ltd; Autobio Diagnostics Co Ltd; QuidelOrtho Corporation; Cancer Diagnostics Inc; Predicine Inc; Strata Oncology; Biocept Inc; Lucence Diagnostics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this In Vitro Cancer Diagnostics market report include:- F. Hoffmann-La Roche Ltd
- Danaher Corporation
- Abbott Laboratories
- Thermo Fisher Scientific
- Siemens Healthineers AG
- Illumina Inc
- Hologic Inc
- Qiagen N.V
- Bio-Rad Laboratories Inc
- Agilent Technologies
- Becton
- Dickinson and Company (BD)
- Sysmex Corporation
- LabCorp Holding Corp.
- Guardant Health
- Quest Diagnostics
- Exact Sciences
- Myriad Genetics Inc
- Natera Inc.
- NeoGenomics Laboratories
- NanoString Technologies Inc
- Caris Life Sciences
- Transasia Bio-Medicals Ltd
- Autobio Diagnostics Co Ltd
- QuidelOrtho Corporation
- Cancer Diagnostics Inc
- Predicine Inc
- Strata Oncology
- Biocept Inc
- Lucence Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 12.36 Billion |
| Forecasted Market Value ( USD | $ 16.78 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
